Lv3
260 积分 2023-07-26 加入
Measurement of ovarian reserve to tailor systemic therapy decisions: future potential or ready for primetime?
1个月前
已完结
乳腺癌GnRHa治疗中的不完全卵巢抑制：定义、监测和应对
1个月前
已完结
GnRHa在绝经前HR阳性乳腺癌中的长期应用管理专家共识（2026版）
1个月前
已完结
Ovarian escape in premenopausal breast cancer: Challenges and strategies for optimizing hormone suppression
1个月前
已完结
Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review
2个月前
已完结
Medication-Related Osteonecrosis of the Jaw
2个月前
已完结
Dalpiciclib plus endocrine therapy in women with HR+/HER2− advanced breast cancer and visceral crisis: a multicenter, nonrandomized, phase 2 DARVIN trial
2个月前
已完结
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
2个月前
已完结
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
2个月前
已完结
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial
2个月前
已完结
皖公网安备34019202002308
